Drug firm Eli Lilly and Company on Monday said it has inked voluntary licensing agreements with Indian drug firms -- Sun Pharma, Cipla and Lupin -- to expedite availability of its arthritis drug Baricitinib for treatment of COVID-19 patients in India.